3 Stocks Peter Lynch Would Love
They could be big winners for patient investors.
Bristol-Myers Squibb
BMY
BMY
$47.74
$0.31
0.7%
BATS BZX Real Time Price as of May 22, 2019, 3:38 p.m.
View Interactive BMY Charts
Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.
News & Analysis: Bristol-Myers Squibb
The Fool has written over 1000 articles on Bristol-Myers Squibb.
All
Market Moves
Podcasts
Earnings
Bristol-Myers Squibb Co (BMY) Q1 2019 Earnings Call Transcript
BMY earnings call for the period ending March 31, 2019.
Bristol-Myers Squibb Posts Solid Q1 Results With the Celgene Acquisition Looming
The big drugmaker beat Wall Street estimates in the first quarter thanks to solid sales growth for its top blockbusters.
Kidney-Cancer Market: Good for Patients, Hard for Investors
Drugmakers battle for patients.
Top Gene-Sequencing Stocks for 2019
These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
Why Celgene Shareholders Should Hold On to Their Bristol-Myers Squibb Stock Once the Acquisition Closes
The fat lady is getting ready to sing with this big pharma deal. Celgene shareholders will soon have a decision to make.
Stock Market Today: Lyft Goes Public
Elsewhere, the merger between Bristol-Myers Squibb and Celgene got some votes of confidence.
Starboard vs. Bristol-Myers Squibb: Who'll Win This Brewing Battle?
An activist investor made a strong argument for walking away from Celgene, but will investors listen?
Why Celgene Stock Dropped 9% Today
Opposition to letting Bristol-Myers eat Celgene is continuing to mount ... among Bristol-Myers shareholders.
Bristol-Myers Squibb's Q4 Earnings Update Shows Why It Needs Celgene
The drugmaker's fourth-quarter results were great. It's the prospects for future quarters that make the Celgene deal look appealing.
